Abstracts 	/ Abstrakts 	
        
        
          - 30) Wellstein A, Palm D, Belz GG. ß-Adrenoceptor
            subtype mediated effects in man in comparison to in vitro ß1
            and ß2 adrenoceptor occupancy. Naunyn-Schmiedeberg's Arch Pharmacol
          1986;322(Suppl.):R 78.
- 31) Tschollar W, Belz GG, Essig J, Runge J, Wellstein A. Fast
            and safe blood pressure reduction from sublingual captopril. J Am
            Coll Cardiol 1987;9:226A.
- 32) Belz GG, Essig J, Wellstein A. Schild plot
            in man with the ACE-inhibitor cilazapril using angiotensin I
            as agonist. Clin Pharmacol Ther 1987;41:232.
- 33) Darius H, Mohr-Kahaly S, Epperlein S, Belz GG. Pharmacodynamics
            of captopril in antagonizing the effect of angiotensin I in
            patients with valvular heart disease. Naunyn-Schmiedeberg's Arch
            Pharmacol 1987;335(Suppl.):R 107.
- 34) Belz GG. Fendiline: Clinical Pharmacological
            Profile of a Ca++-CaM-Antagonist.
  J Mol Cell Cardiol 1987/88;19(Suppl.III):S 5.
- 35) Schäfer-Korting M, Meinicke T, Belz GG.The
            relationship of enoximone pharmakokinethics and pharmacodynamics
            in healthy man. Naunyn-Schmiedeberg's Arch Pharmacol 1988;337(Suppl.):R
            120.
- 36) Breithaupt K, Belz GG, Fraedrich U, Stolzenburg K. Pharmacodynamic
            properties of the PDE III inhibitor and Â1-antagonist
            Saterinone (inn) in healthy volunteers. Naunyn-Schmiedeberg's
            Arch Pharmacol 1988;338(Suppl.):R 78.
- 37) Schloos J, Wellstein A, Pitschner HF, Palm D, Belz
              GG,Schäfer-Korting
              M, Mutschler E. Carteolol (a ß-blocker with partial
              agonistic activity) in comparison to propranolol as determined
              by investigations in man and in vitro radioreceptor assays from
              plasma samples. Naunyn-Schmiedeberg's Arch Pharmacol 1988;338(Suppl.):
 R 78.
- 38) Bliesath H, Belz GG, Wurst W, Essig J, Steinijans VW,
              Neumann B. The effect of 0.9 mg of Niguldipin i.v. on
              blood pressure, heart rate, total peripheral resistance, and
              cardiac output in healthy volunteers. J Cardiovasc Pharmacol 1988;12(Suppl.6):
              S 213.
- 39) Beermann C, Kleinbloesem CH, Belz GG. Influence
            of the angiotensin-converting enzyme inhibitor cilazapril and
            the a1-receptor antagonist prazosin on the response of human hand
            veins in situ to angiotensin I and noradrenaline. Naunyn-Schmiedeberg's
            Arch Pharmacol 1989;339(Suppl.):R 72.
- 40) Belz GG, Beermann C, Schloos J, Kleinbloesem CH.Influence
            of angiotensin-converting enzyme (ACE) inhibition on the response
            of human hand veins in situ to angiotensin I and noradrenaline. Clin
            Pharmacol Ther 1989;45:125.
- 41) Belz GG, Breithaupt K, Erb K, Kleinbloesem CH.Can
            a combination of ACE-inhibitor and ß-blocker be successfully
            used for treatment of hypertension. Clin Pharmacol Ther 1989;45:142.
- 42) Belz GG, Breithaupt K, Erb K, Schroeter V. Noninvasive
            methods to measure cardiovascular drug actions. Europ J Clin Pharmacol
            1989;36(Suppl.):A8.
  <   >   1 2 3 4 5 6 7 8 <